Eledon Pharmaceuticals Inc

NASDAQ:ELDNUnited States

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Contact Information

Headquarters

19900 Macarthur Blvd Ste 550IRVINE, CA, United States 92612-8426

Phone

949-238-8090

Fax

302-655-5049

Executives

Independent Chairman of the Board

Keith Katkin

President, Chief Scientific Officer, Director

Steven Perrin

Chief Executive Officer, Director

David-Alexandre Gros

Chief Financial Officer

Paul Little

Chief Compliance Officer, General Counsel, Corporate Secretary

Bryan Smith